News Roundup

New and Noteworthy Information—August 2013


 

Continuation of lipophilic statin therapy may be associated with a decreased risk of Parkinson’s disease, compared with discontinuation, according to research published online ahead of print July 24 in Neurology. Between 2001 and 2008, investigators recruited participants without Parkinson’s disease who had initiated statin therapy. Among 43,810 subjects, the incidence rate for Parkinson’s disease was 1.68 and 3.52 per 1,000,000 person-days for lipophilic and hydrophilic statins, respectively. Continuation of lipophilic statins was associated with a decreased risk of Parkinson’s disease, compared with statin discontinuation. No association between hydrophilic statins and occurrence of Parkinson’s disease was observed. Among lipophilic statins, a significant association was observed for simvastatin and atorvastatin, especially in females. Long-term use of lipophilic or hydrophilic statins was not significantly associated with Parkinson’s disease.

Erik Greb
Senior Associate Editor

Pages

Recommended Reading

Florbetapir PET may rule out amyloidosis and Alzheimer’s disease
MDedge Neurology
Food for thought: DASH diet slowed cognitive decline
MDedge Neurology
Neil S. Buckholtz, PhD
MDedge Neurology
Miia Kivipelto, MD, PhD
MDedge Neurology
Brain atrophy rate may predict later cognitive decline
MDedge Neurology
Glucose, insulin measures unrelated to AD pathology
MDedge Neurology
Metformin bests other antidiabetics in protection from dementia
MDedge Neurology
Aerobic exercise boosts brain power in mild cognitive impairment
MDedge Neurology
Brain volume loss may be greater in type 1 diabetics with microangiopathy
MDedge Neurology
Delaying Retirement May Reduce Risk for Dementia
MDedge Neurology